News

In comparison with placebo, older adults on low-dose aspirin had an increase in a combination of subdural, extradural, and subarachnoid bleeding.

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.

ANPD001, an autologous cell therapy derived from patient-derived iPSCs, is designed to replace lost dopamine neurons in patients with Parkinson disease.

With the decision, ClarityPro becomes the first and only device to offer new technology add-on payment reimbursement for the diagnosis of electrographic status epilepticus.

The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]

In the supporting phase 3 study, treatment with GA Depot resulted in statistically significant reductions in annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.

As a recap from AAIC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the subgroup findings from the phase 4 NURTURE study of nusinersen (Spinraza; Biogen) in presymptomatic spinal muscular atrophy. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

A group of experts in the care of patients with neurological conditions—Kumar B. Rajan, PhD; Christina Jensen-Dahm, MD, PhD; Nicole Fowler, PhD; Nicholas Ashton, PhD; Jazmyn Muhammad, BS—shared their perspectives on hot topics of treatment and management in Alzheimer disease from the 2023 Alzheimer's Association International Conference.

The time to osteoporosis was 23% faster with exposure to non-enzyme-inducing antiseizure medications and 9% faster for enzyme-inducing ASMs, independent of epilepsy.

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 4, 2023.

The director at the Foundation for the National Institutes of Health discussed relevant biomarkers for Alzheimer disease and their role as novel therapeutics continue to emerge. [WATCH TIME: 5 minutes]

Although treatment with tirofiban improved the odds of excellent outcome, results for the secondary end points did not consistently support the primary end point analysis.

The director of movement disorders at the Banner Sun Health Research Institute discussed the challenges in diagnosing atypical Parkinsonian disorders and the potential role of biomarkers in improving diagnostic accuracy. [WATCH TIME: 5 minutes]

NS-050/NCNP-03, an exon skipping investigational therapy, has been cleared by the FDA for the initiation of a phase 1/2 clinical study for the treatment of Duchenne muscular dystrophy.

Boris Kantor, PhD, associate research professor of neurobiology, and Ornit Chiba-Falek, PhD, professor in neurology, both faculty at Duke University, discussed research on an innovative epigenome therapy targeting the APOE gene, a significant genetic risk factor for Alzheimer disease.

Positive data from the 25 mg cohort study exploring Larimar Therapeutics’ CTI-1601 has been submitted to the FDA, with a meeting scheduled with the agency later this quarter to discuss steps for a phase 2 trial.

The pediatric neurologist at Johns Hopkins Medicine discussed the importance of early diagnosis in SMA, and the notable barriers that come with obtaining disease-modifying therapies. [WATCH TIME: 4 minutes]

After nearly 13 years of follow-up, 36% of patients with relapsing multiple sclerosis had a confirmed Expanded Disability Status Scale score worsening.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]

The combination of digital cognitive behavioral therapy and medication resulted in a sustained improvement in sleep quality compared with monotherapy modalities.

Following a successful first patient treatment experience with TSHA-102, an adeno-associated virus vector-based gene therapy for Rett syndrome, Taysha Gene Therapies was recommended to continue with investigating the therapy in a second patient.

Investigators concluded that the growing and testing of motor neurons from patient-derived induced pluripotent stem cells could be clinically used for the prediction of ropinirole’s efficacy as a treatment for patients with ALS.